FDA Inspection
GlaxoSmithKline BiologicalsGlaxoSmithKline Biologicals – FDA Inspection, Sep 13, 2022
Record Details
This FDA Inspection record concerns GlaxoSmithKline Biologicals, with an inspection on September 13, 2022, issued by the Center for Biologics Evaluation and Research, covering biologics.
- Company
- GlaxoSmithKline Biologicals
- Inspection Date
- September 13, 2022
- Product Type
- Biologics
View Company Profile
ID · b7981ae6-29ac-4d33-bb97-b46c00e4538f
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1179634
- FDA center
- Biologics
- Project area
- Vaccines and Allergenic Products
FDA Citations
1- 21 CFR 211.67(c)Cleaning/maintenance records not kept
Full citation text and observation details available on the Dashboard.
Other FDA inspections of GlaxoSmithKline Biologicals
3| Date | Classification | Office | Project area |
|---|---|---|---|
| June 4, 2024 | Not classified | Office of Inspections and Investigations | |
| March 12, 2024 | VAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| November 13, 2018 | Not classified | Office of Inspections and Investigations |
Other documents for GlaxoSmithKline Biologicals
- FDA Inspection 1242355 - 2024-06-04
- FDA Inspection 1232702 - 2024-03-12
- FDA Inspection 1074672 - 2018-11-13
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.